In litigation, their work has included preparation of opening, rebuttal, and reply reports, development of declarations and technical analyses, and evaluation of drug formulation, stability studies, and prior art. Experience includes deposition testimony and trial testimony in patent infringement matters, along with participation in pre-trial preparation in matters before federal courts and the International Trade Commission, including involvement in ANDA litigation and intellectual property disputes.

This pharmaceutical expert witness is a Ph.D. medicinal chemist with over 25 years of experience in drug research and development, with a focus on the discovery and development of novel human therapeutics. Their work includes consultations, expert report preparation, deposition, and trial testimony in matters involving pharmaceuticals, including Hatch-Waxman ANDA patent infringement, trade secret, trademark infringement, patent infringement, and contract law cases relating to pharmaceuticals.

Their scientific expertise spans multiple stages of drug research and development, including synthesis and purification of drug candidates, in vitro and in vivo testing involving efficacy, pharmacokinetics, and pharmacodynamics, formulation development, dosing routes, stability studies, and management of contract research organizations supporting preclinical testing. Their research has focused on development of therapeutics in anti-infective, anti-inflammatory, and neurodegenerative disease areas, including multiple sclerosis, arthritis, spinal muscular atrophy, tuberculosis, and cancer. This work includes contributions to the discovery and development of preclinical candidates and collaboration with cross-functional teams in cell biology, pharmacology, process chemistry, and external vendors supporting in vivo efficacy, pharmacokinetics, and toxicity studies.

Their work has also included contribution to discovery and development of novel therapeutics recognized with the American Chemical Society Heroes of Chemistry Award, as well as consulting supporting drug development, formulation, and clinical trial-related activities. Additional work includes co-authorship of a pre-IND proposal that received a favorable review by the FDA. Educational background includes a Doctor of Philosophy in Chemistry and a Bachelor of Arts in Chemistry with a minor in Biology.